These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 38703949

  • 1. Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults.
    Jaffe K, Slat S, Chen L, Macleod C, Bohnert A, Lagisetty P.
    J Subst Use Addict Treat; 2024 Aug; 163():209361. PubMed ID: 38703949
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S, Sun L, Vakkalanka JP.
    Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B, El Shahawy O, Segoshi A, Moreno KP, Badiei B, Sarker A, Krawczyk N.
    J Addict Dis; 2021 Aug; 39(1):37-45. PubMed ID: 32835641
    [Abstract] [Full Text] [Related]

  • 7. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
    Bello JK, Xu KY, Salas J, Bedrick BS, Grucza RA.
    J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347
    [Abstract] [Full Text] [Related]

  • 8. Patient and provider medication preferences affect treatment outcomes among adolescents and young adults with opioid use disorder.
    Monico LB, Fletcher JB, Ross T, Schwartz RP, Fishman MJ, Gryczynski J, Mitchell SG.
    J Subst Use Addict Treat; 2024 Jul; 162():209334. PubMed ID: 38531508
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Attitudes toward and training in medications for opioid use disorders: a descriptive analysis among employees in the youth legal system and community mental health centers.
    O'Reilly LM, Schwartz K, Brown SA, Dir A, Gillenwater L, Adams Z, Zapolski T, Hulvershorn LA, Aalsma M.
    Subst Abuse Treat Prev Policy; 2024 Jun 21; 19(1):32. PubMed ID: 38907286
    [Abstract] [Full Text] [Related]

  • 11. Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.
    Madden EF, Prevedel S, Light T, Sulzer SH.
    Subst Use Misuse; 2021 Jun 21; 56(14):2181-2201. PubMed ID: 34538213
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV, Levin FR, Reilly MP, El-Bassel N.
    J Subst Abuse Treat; 2021 Mar 21; 122():108196. PubMed ID: 33221125
    [Abstract] [Full Text] [Related]

  • 14. Comparing Reasons for Starting and Stopping Methadone, Buprenorphine, and Naltrexone Treatment Among a Sample of White Individuals With Opioid Use Disorder.
    Randall-Kosich O, Andraka-Christou B, Totaram R, Alamo J, Nadig M.
    J Addict Med; 2020 Mar 21; 14(4):e44-e52. PubMed ID: 31651562
    [Abstract] [Full Text] [Related]

  • 15. Attitudes toward Medication for Opioid Use Disorder among Substance Use Treatment Providers.
    Pasman E, Lee G, Kollin R, Rodriguez B, Agius E, Madden EF, Resko SM.
    Subst Use Misuse; 2022 Mar 21; 57(12):1828-1836. PubMed ID: 36041008
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.
    Xu KY, Schiff DM, Jones HE, Martin CE, Kelly JC, Bierut LJ, Carter EB, Grucza RA.
    J Gen Intern Med; 2023 Dec 21; 38(16):3499-3508. PubMed ID: 37436568
    [Abstract] [Full Text] [Related]

  • 18. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
    Priest KC, King CA, Englander H, Lovejoy TI, McCarty D.
    Subst Abus; 2022 Dec 21; 43(1):1251-1259. PubMed ID: 35670778
    [Abstract] [Full Text] [Related]

  • 19. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE, Vander Wyk B, Schlossberg EF, Shaw A, Springer SA.
    Addict Sci Clin Pract; 2022 Mar 07; 17(1):15. PubMed ID: 35255967
    [Abstract] [Full Text] [Related]

  • 20. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P, Tossone K, Ashmead R, Bickert T, Bailey E, Doogan NJ, Mack A, Schmidt S, Bonny AE.
    J Subst Abuse Treat; 2022 May 07; 136():108686. PubMed ID: 34953637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.